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Abstract
Microiontophoresis uses an electric current to eject a drug solution from a glass capillary and is 
often utilized for targeted delivery in neurochemical investigations. The amount of drug ejected, 
and its effective concentration at the tip, has historically been difficult to determine, which has 
precluded its use in quantitative studies. To address this, a method called controlled iontophoresis 
was developed which employs a carbon-fiber microelectrode incorporated into a multibarreled 
iontophoretic probe to detect the ejection of electroactive species. Here, we evaluate the accuracy 
of this method. To do this, we eject different concentrations of quinpirole, a D2 receptor agonist, 
into a brain slice containing the dorsal striatum, a brain region with a high density of dopamine 
terminals. Local electrical stimulation was used to evoke dopamine release, and inhibitory actions 
of quinpirole on this release were examined. The amount of drug ejected was estimated by 
detection of a coejected electrochemical marker. Dose response curves generated in this manner 
were compared to curves generated by conventional perfusion of quinpirole through the slice. We 
find several experimental conditions must be optimized for accurate results. First, selection of a 
marker with an identical charge was necessary to mimic the ejection of the cationic agonist. Next, 
evoked responses were more precise following longer periods between the end of the ejection and 
stimulation. Lastly, the accuracy of concentration evaluations was improved by longer ejections. 
Incorporation of these factors into existing protocols allows for greater certainty of concentrations 
delivered by controlled iontophoresis.
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Microiontophoresis is the ejection of solute from a capillary by an electric current. This 
technique has been widely used in neuroscience to deliver agents to specific areas of the 
brain.1–4 While offering advantages over conventional delivery methods, the inability to 
determine ejection quantity or confirm drug delivery has impeded micro-iontophoresis from 
having greater impact. Indeed, the modern use of microiontophoresis is primarily for 
qualitative investigations.5–9 Commonly, the ejection quantity is varied by adjusting the 
magnitude of the ejection current, but such methods are usually carried out without 
confirmation of the delivered amount.10–12 Because similar ejection conditions can result in 
different delivery rates, most users do not make precise claims of their ejection 
concentrations.
Theoretical attempts to determine ejection quantities have assigned transport numbers to 
specific analytes.13 However, slight variations in barrel geometries cause different transport 
numbers between similarly fabricated probes.14 Additionally, the ejection medium may 
influence the concentration distribution, rendering estimates of concentration from the 
ejection quantity meaningless.15,16 Measurement strategies for ejected solutions have shown 
more promise, as electrodes positioned near or adjacent to the barrel can detect the delivery 
of electroactive substances, as can fluorescence measurements for fluorophores, without 
affecting delivery to the adjacent region.17–21 These methods have the advantage of 
providing simultaneous information regarding the ejection progress with locally collected 
physiological data.22–24 One technique for monitoring ejections, controlled iontophoresis, 
employs a carbon-fiber microelectrode incorporated into a multibarreled probe, with the 
remaining barrels used for ejections.25,26 Ejection of an electroactive substance can be 
detected and quantified, and its concentration is related to that of a coejected inactive 
compound if the relative mobilities are known.27 For use in brain tissue, the electroactive 
species, or marker, must be inert to the neurochemical processes under investigation.28
We have previously shown that ejection rates of markers and drugs are consistent and can be 
determined from their mobilities in capillary electrophoresis because the same mass 
transport mechanisms, electroosmotic flow and migration, are operant in both techniques.29 
In this study, ejections of quinpirole (QP), a D2 receptor agonist, were performed with an 
electrochemical marker to estimate the drug delivery quantity. QP inhibits dopamine (DA) 
release in a dose-dependent manner by binding to the autoreceptor on presynaptic DA 
terminals.30 Using the diminished stimulated DA release quantity following QP ejections 
and the electrochemical signal from the marker, we determined the accuracy of calculated 
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ejected drug concentrations. Our initial results had large discrepancies between the 
calculated concentrations and the observed effects. We then determined the causes of the 
poor predictions by evaluating the factors that govern evaluations of ejected concentrations. 
Through this, it is shown how optimized methods can improve assessments of drug 
concentrations in controlled iontophoresis.
EXPERIMENTAL SECTION
Chemicals and Solutions
All chemicals were received from Sigma-Aldrich (St. Louis, MO). Artificial cerebral spinal 
fluid (aCSF) consisted of 126 mM NaCl, 2.5 mM KCl, 1 mM NaH2PO4, 26 mM NaHCO3, 2 
mM MgSO4, 2 mM CaCl2, and 11 mM glucose and adjusted to pH 7.4. Iontophoretic 
solutions were made fresh daily from deionized water, and the pH was consistently 
measured between 6 and 7. To prevent clogging, solutions were filtered (0.45 μm Nylon, 
Nalgene, USA) before addition to the barrel.
Iontophoresis with Fast-Scan Cyclic Voltammetry
Four-barreled iontophoresis probes (0.5–1 μm tip diameter) were fabricated from prefused 
glass capillaries (Friedrich & Dimmock, Millville, NJ) as previously described.27 One of the 
barrels held a capillary containing a carbon fiber (7 μm diameter) cut to approximately 100 
μm while the other barrels were available for ejections. A homemade current source (UNC 
Electronics Facility, Chapel Hill, NC) was used in combination with customized LabVIEW 
code (National Instruments, Austin, TX) to control ejections through an NI-USB-6343 DAQ 
card (National Instruments). For each ejection, a constant current was applied to the barrel 
and the corresponding voltage data was recorded. A single Ag/AgCl reference electrode 
(World Prescision Instruments, Sarasota, FL) held at ground potential was used as the return 
for iontophoretic ejections and for voltammetry experiments.
As the ejection proceeded, ejected electroactive species were detected by fast-scan cyclic 
voltammetry (FSCV) at the carbon-fiber microelectrode using a locally constructed 
instrument (UNC Chemistry Electronics Facility). HDCV software was used to control the 
potential during voltammetry and to collect data.24 For detection of 2-(4-nitrophenoxy) 
ethanol (NPE) with DA or acetaminophen (AP), waveform parameters were chosen so that 
each species could be resolved.29 The waveform began from a −0.7 V holding potential, was 
scanned to −1.3 V, then to 1.0 V, and finally returned to the holding potential. This was done 
at a scan rate of 200 V/s and repeated at 10 Hz. For dose–response experiments, a waveform 
was used which optimized the DA signal.31 This utilized a holding potential of −0.4 V, 
which was then scanned to an upper limit of 1.0 V before returning to the holding potential. 
The scan rate was 600 V/s, and the waveform was repeated at 10 Hz. All voltammograms 
underwent digital background subtraction, averaging, and filtering (2–10 kHz) prior to 
analysis.24
Fluorescence Microscopy
Iontophoretic barrels were filled with a 10 mM tris(2,2′-bipyridyl)dichlororuthenium(II) 
(Ru(bpy)3Cl2) and 5 mM NaCl solution. A micromanipulator (MPC-200-ROE, Sutter 
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Instruments, Novato, CA) was used to insert the barrel tip ~50 μm beneath the surface of a 
1% agarose block made from aCSF, which was positioned in a holding chamber on the stage 
of an Eclipse FN1 microscope (Nikon Instruments). Additional aCSF was added around the 
agarose in which the Ag/AgCl reference electrode was placed. The microscope was 
equipped with a xenon halide illumination source (X-Cite 120, EXFO), and filter cubes were 
used to select the excitation (450–490 nm) and emission (500–550 nm) wavelengths. Images 
were captured with a Retiga Exi camera (QImaging, Surrey, BC, Canada) at a resolution of 1 
pixel/μm and recorded with QCapture software (QImaging).
Ejections of Ru(bpy)3Cl2 (120 nA) were performed for 5, 15, or 60 s, and images were 
recorded every 3–10 s. Additional images were recorded for 1 min following ejection 
termination. A Matlab script (Mathworks, Natick, MA) was used to determine the average 
radial Ru(bpy)32+ distribution of each image by averaging the fluorescence intensity along 
11 background subtracted cross-sectional lines spanning from the barrel tip.32
Animal Care and Use
Sprague–Dawley male rats (250–350 g, Charles River, Wilmington, MA) were used for all 
in vitro experiments. Prior to use, rats were dually housed and provided with food and water 
ad libitum. Procedures were approved by the Institutional Animal Care and Use Committee 
at the University of North Carolina at Chapel Hill. Special care was taken to limit the 
number of animals used and to reduce their suffering.
Brain Slice Preparation
Following urethane (1.5 g/kg) anesthesia, brains were quickly removed and placed in chilled 
oxygenated (95/5% O2/CO2) aCSF. A vibratome (VF-200, Precisionary Instruments, San 
Jose, CA) equipped with a stainless steel feather blade (Fendrihan, USA) was used to cut 
300 μm thick coronal slices containing the anterior dorsal striatum. After cutting, slices were 
allowed to recover for at least 1 h in 20 °C aCSF. For recordings, slices were anchored 
(SHD-22KIT, Warner Instruments, Hamden, CT) in a perfusion chamber (RC-22, Warner 
Instruments) on the microscope stage. A continuous (2 mL/min) stream of 37 °C oxygenated 
aCSF was perfused through the chamber. A 30 min equilibration period in the perfusion 
chamber was assigned for each slice prior to measurements.
Dose–Response Curves
A bipolar tungsten electrode with 250 μm spacing (MicroProbes, Gaithersburg, MD) was 
used to evoke DA release. It was inserted ~50 μm below the surface of a brain slice in the 
dorsal striatum. Release was evoked by a single 350 μA biphasic pulse (2 ms/phase) and 
detected using FSCV at a carbon-fiber microelectrode positioned midway between the 
stimulating electrodes. To avoid electrical interference, the stimulation was applied 10 ms 
before the FSCV waveform. Release was evoked at 4 min intervals. After an initial 
conditioning phase of approximately 30 min, DA release was stable, changing by less than 
10% between stimulations.30,33 To apply QP via perfusion, the standard aCSF stream was 
switched to aCSF containing a known concentration of the drug. Stimulation continued 
every 4 min until released DA stabilized at a new concentration, typically achieved within 
20–30 min.34 This value was taken as the effect of the drug and was compared to predrug 
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release. Dosages were applied in increasing order, with no more than four concentrations per 
slice.
For iontophoretic experiments, the carbon-fiber micro-electrode was incorporated in a 
multibarreled probe, positioned in the dorsal striatum at a location similar to those in the 
perfusion experiments. Identical biphasic electrical stimulations were used, and coejections 
(5, 15, or 60 s) of QP and an electrochemical marker were performed after consistent DA 
release was established. Stimulation occurred at precise times after the ejection (3, 15, or 60 
s). The amount of DA released from stimulation after the ejection was recorded as the 
postdrug release quantity. Ejections were timed so that a 4 min stimulation rate was 
maintained. To allow recovery from previous administration, two stimulations were 
performed between successive ejections. AP and DHBA were used independently as 
markers to monitor ejections via oxidation on the carbon-fiber electrode. For AP trials, a 1 
mM solution of the marker, 0.3 μM QP, and 5 mM NaCl was ejected. For DHBA, the 
concentrations of the marker, QP, and NaCl were chosen on the basis of the ejection duration 
and time before stimulation to allow for complete coverage of the dose–response curve and 
to ensure for detection of the marker within the linear calibration range. Exact barrel 
concentrations are reported individually for each case.
Statistical Analysis of Dose–Response Data
Regression curves and parameters for dose–response data were determined in Prism 
(GraphPad Software, La Jolla, CA) using a sigmoidal dose–response (variable slope) model, 
which employs a four parameter logistic Hill equation to fit data. Constraints were applied 
for the maximum equal to 1.0 and the bottom less than or equal to 0.2. These were required 
for several iontophoresis data sets (AP and DHBA with 3 s wait time) which displayed 
highly varied responses and were chosen on the basis of perfusion results. All p-values 
reported for the best-fit parameters were calculated using the comparison method with an F 
test.
RESULTS AND DISCUSSION
Advantages of Microiontophoretic Drug Delivery
Quantitative drug application is challenging in neurochemical investigations. Doses 
administered in vivo are typically based on the animal’s mass, but uptake and metabolism 
ultimately determine the effective concentration at the region of interest. In vitro 
experiments can more reliably perfuse known concentrations throughout a brain slice, but 
long application times are required to attain equilibrium. The perfusion procedure we 
employed is illustrated in Figure 1A. A carbon-fiber microelectrode was used to detect DA 
by FSCV in the dorsal striatum of a rat brain slice. The DA signal increased directly 
following electrical stimulation and returned to baseline shortly after. Failure to return to the 
exact baseline could be due to chemical interferences or electrode drift.35 After the predrug 
release stabilized, 30 nM QP was administered. Evoked DA release gradually decreased 
during perfusion until a new stable release quantity was achieved. Due to the time required 
for the drug to diffuse into the slice, its full inhibitory effect was not realized until nearly 20 
min after its application.
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In contrast, locally delivered drugs from microiontophoresis take effect in seconds which 
allows for more rapid investigations. To illustrate this, Figure 1B shows a controlled 
iontophoresis ejection in which the oxidation current of a coejected marker, DHBA, was 
monitored by FSCV on a carbon-fiber microelectrode during QP delivery. The inhibitory 
effect of QP on stimulated DA release was observed 15 s after the ejection (Figure 1C).
Concentration Evaluations of Controlled Ejections
To determine concentrations of ejected species from controlled iontophoresis, eq 1 was used 
where im is the marker current at the end of the ejection, Am is a flow-analysis calibration 
factor, [M]b and [D]b are the respective marker and drug barrel concentrations,  is their 
mobility ratio in an electric field, and DF is a dilution factor.28
(1)
The marker current, calibration factor, barrel concentrations, and electric mobility ratio 
provide the average concentration of the marker at the end of the ejection. The dilution 
factor adjusts for the amount of drug remaining at the time of stimulation, typically 5–120 s 
after the ejection is terminated. This value is empirically determined by the fraction of the 
marker oxidation current at the stimulation time compared to its steady-state value (Figure 
1B). The ability of eq 1 to yield ejection concentrations was tested by comparing responses 
of controlled iontophoresis to those obtained from perfusion of QP, the standard drug 
delivery method for slice experiments. For perfusion, known QP concentrations were 
administered to the slice and the electrically evoked DA response was recorded after a new 
stable value was obtained. This quantity was compared to the predrug release amount, and as 
indicated by the error bars, results were highly reproducible (Figure 2, squares). Best-fit 
parameters from a four parameter Hill regression model yielded an IC50, the drug 
concentration which inhibits maximal release by half, of 37 nM, a Hill slope, indicating the 
cooperativity at the binding site, of −1.28 (Table 1), and a reasonable value of the correlation 
coefficient.36 Each of these parameters agrees with previously reported values.37,38 Next, 
dose–response data were collected for controlled iontophoretic delivery of QP, a monocation 
at the pH values employed. In these initial experiments, AP, a neutral molecule, was used as 
the electroactive marker. Ejections were 15 s in length, and DA release was evoked 15 s after 
the end of the ejection, with data obtained from 5 different iontophoretic probes due to barrel 
to barrel ejection variability.39 Figure 2 (circles) shows the DA response to iontophoretic 
delivery of QP using eq 1 to evaluate ejection concentrations. These data have two major 
differences compared to the perfusion data. First, as reflected by the low correlation 
coefficient, the data were highly scattered and displayed a considerable degree of variance. 
Second, concentration estimates systematically underestimated the effective value, as a 
significantly different IC50 (P < 0.0001) was determined between delivery modes. Thus, 
controlled iontophoresis failed to produce either accuracy or precision in evaluation of 
ejected concentrations.
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Initial Ejection Behavior Influenced by Molecular Charge
To understand the failure of eq 1 to reliably predict concentrations, the behavior of coejected 
species was further examined by ejecting a solution of DA, a protonated monocation at 
physiological pH, and the neutral molecule NPE into aCSF. These two compounds can be 
individually detected by FSCV during their coejection. Since mass transport in iontophoresis 
is a consequence of electroosmotic flow (EOF) and migration, ejection rates are dependent 
upon molecular charge and size.29,40,41 Because these molecules are similarly sized, 
variation in their transport is primarily due to their charge difference, with EOF acting 
equally on both molecules while only DA is affected by migration. Temporal ejection 
profiles revealed a clear delay in NPE ejection compared to DA (Figure 3A). This indicates 
that initiation of mass transport by EOF lags that of migration.
The delayed action of EOF is due to the time required to eject the interfacial layer from the 
barrel tip. The interfacial layer is a heterogeneous region created by exchange between the 
barrel solution and the ejection medium during the time between ejections.42 When the 
ejection was initiated, the voltage increased stepwise and rose more gradually as time 
progressed (Figure 3B). More voltage was required to maintain a constant ejection current 
because the highly ionic interfacial layer in the barrel tip was first ejected, increasing the 
total resistance of the barrel solution. Once this layer was cleared, the voltage approached 
steady state, and EOF was initiated.
Ejection Current Affects Interfacial Layer Clearance Time
To further characterize combined delivery, the experiment was repeated using different 
ejection currents that followed 3 min waiting periods. Differences in the ejected quantities of 
DA and NPE were more apparent at lower ejection currents (Figure 4A, upper). Further, the 
ratio of the faradaic current between the two species at the end of the ejections was 
dependent on the ejection current (Figure 4B, upper, ANOVA, p = 0.0016). This is because 
larger currents more quickly cleared the interfacial layer from the tip, which afterward 
allowed for the ejection of bulk barrel solution. For weaker ejections, the interfacial layer 
took longer to eject and, in some instances, was not cleared.
The problem of differential ejection rates was remedied by ejecting species of similar charge 
(Figure 4A, lower). When DA was replaced with AP, ejected quantities of the two neutral 
species were similar regardless of the ejection current (Figure 4B, lower, ANOVA, p = 
0.090). These experiments explain why the neutral AP marker failed to reliably track the 
ejection of positively charged QP in the controlled iontophoresis dose–response experiment. 
Delayed EOF at the onset of ejections resulted in the delivery of the drug without the 
marker, leading to inconsistent and underestimated concentrations. Although we have 
previously documented significant EOF in barrels of high ionic strength (200 mM), these 
measurements were made for ejections lasting multiple minutes from barrels which were 
fully primed beforehand.43 Continuous ejections of this sort prohibit the formation of an 
interfacial layer and, indeed, are often employed specifically for this purpose.44,45 
Additional work comparing DA and NPE ejection rates involved rapidly alternating between 
ejection and rest periods, conditions which similarly minimize the interfacial layer.29 The 
key difference in the current study is that an interfacial layer was allowed to form during a 3 
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min waiting period prior to ejections, which caused the delay in EOF. Thus, the electric 
mobility term of eq 1  correcting for different ejection rates between dissimilarly 
charged species is dependent on the time required to eject the interfacial layer. However, as 
demonstrated, this term can be disregarded when the charge and molecular size of ejected 
species are similar because analytes of comparable mobility exhibit similar ejection 
behavior.
Reevaluating Ejection Concentrations with Modified Approaches
To further examine the failure of eq 1 to properly evaluate concentrations from controlled 
iontophoresis, the solute distribution of ejections was studied using fluorescence 
microscopy. Ru(bpy)32+, a cationic fluorophore, was ejected into a 1% agarose gel which 
produces a similar distribution as ejections in brain tissue.32 A color plot of the fluorescence 
intensity after 15 s of continuous ejection is shown in Figure 5A, which demonstrates how 
the maximum intensity occurs at the barrel tip and decays with spherical symmetry. 
Following a 15 s period with the ejection current turned off, the same distribution becomes 
much more uniform (Figure 5B). The time-course of the intensity at different locations 
during and following 15 s ejections is shown in Figure 5C. Due to the symmetrical nature of 
the distribution, these intensities represent the concentration on a sphere of radius r around 
the ejection point. Reduced concentrations after the ejection show the importance of the 
dilution factor (DF) in eq 1, which to this point was determined by the ratio of the marker 
current at stimulation compared to the steady state value. However, due to solute adsorption, 
concentration heterogeneity, and capacitive drift of the electrode, we feared this method was 
susceptible to error.46 Instead, DF was determined from the fluorescence data. Figure 5D 
shows the average fluorescence intensity as a function of distance along the carbon fiber at 
the end of 15 s ejections and again for various waiting periods after the ejection was 
terminated. Each profile was integrated over a sphere to reveal the total amount of solute 
present. The ratio of the quantity after the waiting period compared to that at the end of the 
ejection gave the new fraction for DF. This value for the 15 s waiting period, 0.55, was 
larger than that obtained using the electrochemical estimate, 0.14, which resulted in the 
underestimated concentrations.
To study the ability of controlled iontophoresis to determine ejection concentrations with the 
updated dilution and mobility factor corrections, dose–response data were obtained for QP 
using DHBA as the electrochemical marker. Like QP, DHBA is a monocation, but it is 
electroactive and was found not to affect DA release in the striatum. Figure 6A shows that, 
unlike the results obtained with AP as the electroactive marker (Figure 2), evaluations using 
DHBA had a good correlation across multiple barrels and ejection current magnitudes (r2 = 
0.887). Thus, the imprecision of the data in Figure 2 was greatly improved by the use of a 
marker with an identical charge as the drug. However, neither this nor the new method for 
DF resolved the issue of inaccuracy, as the IC50 was overestimated by more than an order of 
magnitude (Table 2).
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Drug Dilution to a Uniform Distribution Improves Precision
The waiting period between the end of the ejection and stimulation was next examined to 
determine its role on concentration evaluations. Dose–response data were generated using 15 
s ejections with DHBA as the marker for waiting periods of 3 and 60 s (Figure 6B). The 
difference between IC50 values was insignificant, indicating that the duration of the waiting 
period did not affect accuracy (Table 2, p = 0.774). However, data for the 3 s waiting period 
were more weakly correlated compared to 15 and 60 s intervals. Thus, we concluded that an 
insufficient waiting period before stimulation can decrease precision, which could be due to 
several factors. First, shorter waiting periods result in a less uniform concentration across the 
electrode at the time of stimulation (Figure 5D). Terminals with D2 receptors are densely 
populated, and released DA diffuses only a few micrometers in the extracellular space before 
its uptake back into neurons.47,48 This means that homogeneous DA release across the 
electrode necessitates a uniform drug concentration along the length of the carbon fiber, 
which can only be achieved with longer waiting periods. Second, the drug concentration 
around the electrode is less variable with longer times (Figure 5C). The half-life for 
dissociation of QP to D2 receptors is ~0.15 s,49,50 so waiting periods spanning multiple half-
lives allow more time for the drug and receptor to equilibrate at diluted concentrations. 
Interestingly, dilution to a nearly uniform and stable conformation occurs relatively quickly 
once ejections are terminated.
This is because the highest concentrated region accounts for only a fraction of the solute 
delivered during the ejection. Indeed, spherical integration of the fluorescence data for the 0 
s profile in Figure 5D reveals that just 0.3% of ejected species are within 10 μm of the 
ejection origin, while more than 77% is located outside of 50 μm. Due to the spherical 
nature of the distribution, by which the volume increases with the third power of the radius, 
regions further away contain the majority of drug and more strongly influence the 
concentration upon dilution. Thus, a moderate wait time (15 s) after ejections is sufficient to 
form a more homogeneous concentration along the electrode.
Ejection Time Affects Accuracy of Concentration Evaluations
The effect of the ejection time was next examined by comparing QP dose–response data for 
5 and 60 s ejections. Delivery was monitored with DHBA and DA stimulation occurred 
following a 15 s waiting period. Concentration evaluations grew more accurate with longer 
ejection times, and the IC50 better matched the perfusion standard (Figure 7A, Table 3). To 
determine why this occurred, the solute distribution for each duration was examined using 
fluorescence microscopy. As shown in Figure 7B, both ejections resulted in a concentration 
gradient along the electrode. These gradients are problematic because the average 
concentration of the ejection bolus, which the marker current is intended to represent, does 
not equal the average concentration along the electrode, which the marker current actually 
measures. Again, this is explained by the spherical distribution of ejected species, whose 
volume is not appropriately weighted by the marker current. For example, according to the 5 
s profile, 25% of the marker current is produced within the first 10 μm of the electrode, 
despite this region containing just 0.5% of the total ejected species. Thus, smaller, more 
concentrated centers of spherical distributions disproportionately contribute to the marker 
current, leading to overestimated values of the average concentration.
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Longer ejection durations resulted in more accurate IC50 values because they had less severe 
concentration gradients at the end of ejections. Since regions further from the origin become 
more concentrated with time, they are better represented by the concentration near the 
ejection point that dominates the marker signal. However, even the IC50 for the 60 s 
ejections significantly differed from that of perfusion (p < 0.0001), which we attribute to 
several factors. First, after 60 s of continuous delivery, the ejection concentration profile was 
still nonuniform along the electrode. Ideally, the distribution would be homogeneous to 
match the flow-injection analysis calibration conditions, but this is not achievable using 
extended ejections.43 Second, biofouling on the surface of untreated carbon-fiber electrodes 
reduces sensitivity.51,52 In fact, calibration following a 45 min incubation period in a slice 
revealed a decreased response of up to 80% in the current study. Lastly, some receptors may 
desensitize with prolonged exposure to drug, resulting in unreliable responses at the time of 
stimulation. However, this was unlikely the case in the current study, as D2 receptors are 
resilient to persistent exposure of QP.53–55
Even when optimized, there exists more quantitative uncertainty in concentrations 
determined from controlled iontophoresis than perfusion. However, in certain circumstances, 
the benefits of iontophoresis could well be worth this small sacrifice. This is because drugs 
can be administered more quickly by iontophoresis, with the combined ejection and waiting 
period lasting only 85 s for the most accurate parameter set (Figure 7A). In contrast, drugs 
delivered by perfusion require 10–20 min before their full effect is observed. Not only does 
faster administration increase throughput, but also it preserves slice health and receptor 
sensitization which are susceptible to prolonged application periods. Ultimately, the choice 
of a delivery method will depend upon the demands of the application, but as shown, 
controlled iontophoresis can provide a reliable drug delivery alternative for neurochemical 
investigations.
CONCLUSIONS
We have demonstrated methods to improve the accuracy and precision of concentration 
evaluations in controlled iontophoresis. To decrease uncertainty in the ejection status of a 
drug, markers should be used which share a similar molecular size and charge. For greater 
consistency in evoked responses, a moderate 15 s waiting period between the end of the 
ejection and stimulation allows the drug concentration to become more uniform. Finally, 
longer ejection times increase the accuracy of evaluations by decreasing the concentration 
gradient along the electrode. While concentration evaluations determined from controlled 
iontophoresis are still imperfect, these improvements, coupled with the benefits of highly 
localized application, offer advantages for investigations of drug effects.
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Figure 1. 
Comparison of drug administration by perfusion and controlled iontophoresis in the dorsal 
striatum of a brain slice. (A) Electrically evoked DA release was monitored with a 
microelectrode during perfusion of 30 nM QP. The released amount before drug (termed 
predrug, dashed gray line) was established, and the perfusion stream was switched to aCSF 
containing QP; this time was taken as t = 0. Stimulation continued every 4 min (blue bars) 
until the new release quantity was stable. (B) Controlled iontophoretic delivery of QP. An 
iontophoretic probe containing a carbon-fiber microelectrode was used to eject a solution of 
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QP, DHBA, and NaCl (0.4, 0.2, 5 mM, respectively) at 15 nA for 60 s (red bar). The 
oxidation of DHBA upon ejection was detected by FSCV performed on the electrode. DA 
release was elicited 15 s after the end of the ejection and was also detected by the carbon 
fiber. (C) Comparison of pre- and postdrug DA release following the ejection in (B).
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Figure 2. 
Dose–response data for the effect of QP on stimulated DA release in the dorsal striatum. QP 
was delivered by perfusion (squares, n = 5 per concentration) or controlled iontophoresis 
(circles). Iontophoretic ejections (5 ejections from 5 unique probes) were monitored using 
AP, and QP concentrations were evaluated using eq 1. Error bars for perfusion represent the 
SEM.
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Figure 3. 
Combined delivery of differently charged species. (A) Faradaic current versus time traces for 
DA (blue) and NPE (green) during coejection. A solution of 1 mM DA, 11 mM NPE, and 5 
mM NaCl was ejected (red bar) into aCSF while a carbon-fiber microelectrode was used to 
monitor delivery. (B) Ejection voltage required to supply 30 nA for the ejection in (A).
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Figure 4. 
Variation in delivery profiles of coejected species with ejection current. (A) Representative 
current versus time traces for coejected species when ejected using different currents. 
Delivery from barrels containing 1 mM DA (blue) and 11 mM NPE (green) reveal 
differential ejection amounts with the ejection current magnitude (upper). Solutions of 5 mM 
AP (orange) and 11 mM NPE (green) resulted in similar delivery profiles (lower). All 
profiles were normalized to the maximum value obtained during the 50 nA ejection. 
Solutions also contained 5 mM NaCl. (B) Ratio of the maximum faradaic current of 
coejected species for NPE/DA (upper) and NPE/AP (lower).
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Figure 5. 
Distribution of ejected solute during and after iontophoretic delivery. (A) Color plot of 
Ru(bpy)32+ fluorescence intensity at the end of a 15 s ejection and (B) the same distribution 
after a 15 s waiting period during which the ejection current was disabled. The location of 
the carbon-fiber electrode (black) and iontophoretic barrel (light blue) are indicated by the 
overlaid representation. (C) Fluorescence intensity on a sphere of radius r centered at the 
ejection origin during and following ejection (n = 8). All values were normalized to the 
maximum intensity 10 μm from the ejection point. The red bar represents the ejection time, 
and the dashed vertical lines indicate its initiation and termination. (C) Distribution of 
ejected solute along the length of the carbon-fiber electrode at select time points following a 
15 s iontophoretic delivery.
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Figure 6. 
Controlled iontophoretic dose–response data for QP administration using DHBA to monitor 
ejections. (A) Responses following 15 s ejections with a 15 s waiting period. (B) Dose–
response data for 3 and 60 s waiting periods following 15 s ejections. For all ejections, eq 1 
was used to evaluate concentrations using the fluorescence dilution factor (DF = 0.94, 0.55, 
and 0.25 for the 3, 15, and 60 s waiting periods, respectively). Barrels contained 0.2 mM 
DHBA and 0.05 mM QP for the 3 and 15 s waiting periods. For 60 s, this was increased to 
0.4 mM DHBA and 0.2 mM QP. All barrels contained 5 mM NaCl, and each data set is 
comprised of 5 ejections from 5 unique probes.
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Figure 7. 
Ejection length increases accuracy of concentration evaluations. (A) Dose–response data for 
5 and 60 s controlled iontophoretic ejections with a 15 s waiting period. Ejections were 
monitored using DHBA, and eq 1 was used to evaluate ejection concentrations (DF was 0.63 
and 0.62 for 5 and 60 s ejection periods, respectively). Barrels performing 5 s ejections 
contained 0.4 mM DHBA and 0.1 mM QP in 5 mM NaCl, which was changed to 0.2 mM 
DHBA and 0.0125 mM QP in 10 mM NaCl for 60 s ejections. Each data set includes 5 
ejections from 5 unique probes. (B) Solute distribution following ejections and a 15 s 
waiting period. Ejections of Ru(bpy)32+ were performed into agarose for 5 and 60 s (n = 8). 
For each case, the fluorescence was normalized to the maximum value at the end of the 
ejection.
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Table 1
Parameters of Perfusion and Iontophoretic Dose-Response Data for QP Administration and Its Effect on 
Stimulated DA Releasea
perfusion iontophoresis
log(IC50) −7.43 ± 0.04 −9.57 ± 0.83
Hill slope −1.28 ± 0.12 −0.68 ± 0.83
r2 0.966 0.296
a
Parameters are from analysis of data shown in Figure 2 using a four parameter Hill model. Perfusion trials utilized 5 measurements at each 
concentration. Iontophoretic data was obtained by 5 ejections from 5 different probes. AP was used as the electrochemical marker, and 
concentrations were evaluated using eq 1. Entries indicate the value and SEM.
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Table 2
Parameters of Iontophoretic Dose-Response Data for QP Administration on Stimulated DA Release Following 
Different Waiting Periodsa
3 s 15 s 60 s
log(IC50) −5.32 ± 0.99 −6.25 ± 0.42 −5.72 ± 0.31
Hill slope −0.51 ± 0.26 −0.83 ± 0.24 −0.71 ± 0.16
r2 0.723 0.887 0.906
a
The time indicates the duration between the end of the ejection and DA stimulation. Parameters reflect data displayed in Figure 6A,B, which were 
obtained by 5 ejections from 5 different probes. DHBA was used to monitor ejections, and concentrations were evaluated using eq 1 with the 
updated fluorescence DF method. A four parameter Hill model was used to evaluate parameters, and entries indicate the value and SEM.
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Table 3
Parameters of Iontophoretic Dose-Response Data for QP Administration on Stimulated DA Release Following 
Different Ejection Durationsa
3 s 15 s
log(IC50) −5.96 ± 0.14 −6.84 ± 0.15
Hill slope −1.25 ± 0.27 −0.90 ± 0.16
r2 0.876 0.941
a
The time indicates the ejection duration, which was followed with a 15 s waiting period before DA stimulation. Parameters represent data in 
Figure 7A, obtained by 5 ejections from 5 different probes. Concentrations were evaluated from eq 1 using the DHBA marker current and updated 
DF term.
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